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Background: Mutations in the KRAS gene are associated with poor response to epidermal growth factor receptor
inhibitors used in the treatment of metastatic colorectal cancer. Factors influencing KRAS test results in tumor
specimens include: tumor heterogeneity, sample handling, slide preparation, techniques for tumor enrichment, DNA
preparation, assay design and sensitivity. We evaluated comparability and consistency of KRAS test results among
five laboratories currently being used to determine KRAS mutation status of metastatic colorectal cancer specimens
in a large, multi-center observational study.
Findings: Twenty formalin-fixed paraffin-embedded human colorectal cancer samples from colon resections
previously tested for KRAS mutations were selected based on mutation status (6 wild type, 8 codon 12 mutations,
and 6 codon 13 mutations). We found good agreement across laboratories despite differences in mutation
detection methods. Eighteen of twenty samples (90%) were concordant across all five labs. Discordant results are
likely not due to laboratory error, but instead to tumor heterogeneity, contamination of the tumor sample with
normal tissue, or analytic factors affecting assay sensitivity.
Conclusions: Our results indicate commercial and academic laboratories provide reliable results for the common
KRAS gene mutations at codons 12 and 13 when an adequate percentage of tumor cells is present in the sample.
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Background and hypothesis
Anti-epidermal growth factor receptor (EGFR) monoclo-
nal antibodies are approved for the treatment of meta-
static colorectal cancer (CRC). However, these anti-
EGFR therapies do not benefit patients whose tumors
harbor a KRAS mutation [1]. Genetic testing for the
presence of KRAS mutations has been recommended to
guide treatment for these patients [2].
Several factors can influence KRAS mutation testing
results in CRC specimens [3-5]. The purpose of this
study was to evaluate comparability and consistency of
clinical KRAS test results among laboratories used to de-
termine KRAS mutation status in a large multi-center
study. Three commercial laboratories (Genzyme, Clari-
ent, Quest Diagnostics), one clinical academic laboratory* Correspondence: heather.s.feigelson@kp.org
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reproduction in any medium, provided the or(Henry Ford Health System), and one academic research
laboratory (Molecular and Medical Genetics, Oregon
Health and Science University) were contracted to
analyze KRAS mutation status for comparison with pre-
vious clinical results. While all five laboratories are Clin-
ical Laboratories Improvement Act (CLIA) certified, they
have different sample preparation and mutation detec-
tion methods. Our aim was not to certify these labora-
tories, but to ensure that we could combine data from
previously tested clinical samples in our research study.
Methods
Twenty surgical specimens from colon resections were
used; eighteen specimens were adenocarcinomas, two
were carcinomas. Blocks were reviewed by a pathologist
to determine whether the samples were of sufficient
quality and quantity for testing, then the samples were
de-identified and slides were prepared per individual la-
boratory specifications. Our intention was to replicate
routine sample testing of clinical specimens as much asral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Specimen requirements and assay specifications of KRAS genotyping by laboratories
Lab #1 (Sequencing) Lab #2 (Sequencing) Lab #3 (Sequencing) Lab #4 (Primer Extension) Lab #5 (Real Time PCR)
Specimen Requirements Preferred sample type*:
Slides from FFPE block 1
H&E stained slide sections
with tumor circled; 4
matching unstained
slides,10 microns each.
Preferred sample type: Archival
FFPE or frozen surgical biopsies
confirmed to contain >50%
tumor by a surgical pathologist.
1 H&E slide; 5 unstained
sections,10 microns each.
Preferred sample type:
FFPE tissue 6 unstained
sections,10 microns each.
Preferred sample type: Pre-cut
slides from FFPE. Send all slides within
5–7 days of cutting. Air dry. Do not
oven dry. Store specimen at room
temperature (20–23.5°C). 5 unstained
sections, 7 microns each
Preferred sample type:
FFPE block, unstained
slides, or fresh snap frozen
biopsy 5 unstained sections,
7 microns each
Genotyping Method: PCR amplification
followed by Direct Sanger
sequencing (Big Dye v. 1.1)
Detected mutations: KRAS




ABI 3100. Detected mutations:




codons 12,13 and 61
Method: Single nucleotide
primer extension with fragment
analysis by capillary electrophoresis
using a modified SNaPshot assay.





KRAS codons 12 and 13
Lower Limit of Detection 20% when≥ 40%
tumor cells present
20% 15-20% 10% when≥ 2% tumor cells present 1-5%
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varied slightly by laboratory. All laboratories used micro-
dissection for tumor enrichment when necessary, but
mutation detection methods differed. Methods for each
laboratory are described in Table 1.
KRAS test results were compared across labs, and dis-
crepancies were evaluated further. This study was
approved by the Institutional Review Boards (IRB) at
Kaiser Permanente Colorado and Kaiser Permanente
Northwest (the Oregon Health and Science University
IRB ceded authority to Kaiser Permanente Northwest).Results
Twenty formalin-fixed paraffin-embedded (FFPE) CRC
samples previously tested clinically for KRAS mutations
by sequencing were selected based on mutation status (6
wild-type samples, 8 with codon 12 mutations, and 6
with codon 13 mutations) from two study sites (Kaiser
Permanente Colorado and Northwest). Patients ranged
in age from 46–85 years; specimens were collected be-
tween 2005–2009. We found good agreement in KRAS
test results with prior clinical results despite differences
in mutation detection methods (Table 2). Eighteen ofTable 2 Results of KRAS testing by five CLIA-certified laborato
Sample ID Clinical Result* Sequencing Lab 1 Sequencing Lab 2
1 WT** WT WT
2 WT WT WT
3 WT WT WT
4 WT WT WT
5 WT WT WT
6 WT WT G12D
7 G12V G12V G12V
8 G12D G12D G12D
9 G12V G12V G12V
10 G12S G12S G12S
11 G12V G12V G12V
12 G12C G12C G12C
13 G12V G12V G12V
14 G12D WT† G12D
15 G13D G13D G13D
16 G13D G13D G13D
17 G13D G13D G13D
18 G13D G13D G13D
19 G13D G13D G13D
20 G13D G13D G13D
*Samples were selected for testing based on these prior clinical results.
**WT: wildtype; G12D: p.Gly12Asp; G12V: p.Gly12Val; G12S: p.Gly12Ser;
G13D: p.Gly13Asp.
†This laboratory did see some evidence that the sample had a mutation, but was be
approximately 40%, which is at the lower level of detection for this laboratory.twenty samples (90%) were concordant across all five la-
boratories, and the mutation type was always consistent.
One laboratory reported a wild-type result for sample
14 which was actually a p.Gly12Asp (G12D) mutation.
While this sample was confirmed to contain an accept-
able 40% tumor cells, tumor heterogeneity in this sample
may have resulted in the variant being present below the
pre-determined 20% threshold. A very small electropher-
ogram peak indicating a c.35 G>A change was visible
by sequencing indicating p.Gly12Asp mutation, but was
not reported because it was below acceptable level of
confidence per laboratory protocol.
We also found a discrepancy in sample 6. The initial
clinical result was wild-type; two labs reported a muta-
tion in exon 12 p.Gly12Asp, and three labs were consist-
ent with the clinical results (wild-type). We evaluated
this discrepancy first by sending additional slides (from
the same tumor block) to the two laboratories that
reported the mutation. These slides were assigned a new
study number to blind the laboratory to the re-testing.
Laboratory #2 found the same result (p.Gly12Asp) in the
second set of slides, but there was not enough tumor tis-
sue for laboratory #3 to reliably genotype. Next, we used
a second FFPE block from the same patient to send aries





















low the confidence threshold. This specimen showed tumor enrichment of
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ies 1–3. Results from this block were concordant at all
three laboratories (KRAS wild-type). Finally, we asked la-
boratories #1 and #2 to “swap” aliquots of the extracted
DNA from their original sample 6 FFPE slides. This re-
analysis confirmed the initial (discrepant) results at each
laboratory. Thus, we conclude that the laboratory results,
while different, are accurate for the sample of tissue
received at each laboratory. The discrepant results could
be due to either true tumor heterogeneity or contamin-
ation of the tumor sample with normal tissue. We can-
not conclusively determine which of these two scenarios
is responsible for our observed results, nor eliminate the
possibility that a laboratory error resulting in sample
mix-up lead to the discrepant results.
Discussion
We found high concordance of KRAS test results with
previously received clinical results across five laborator-
ies, despite differences in laboratory methods. The dis-
cordant results observed in two samples are most likely
due to sample characteristics rather than to laboratory
error. Our study focused only on mutations in codons 12
and 13 of KRAS. These are the most common mutations
and are often the only mutations targeted in clinical test-
ing. However, other mutations may have clinical implica-
tions and were not included in our study [6,7].
We limited our study to samples from colon resec-
tions. Samples with smaller volume, such as from meta-
static sites or biopsy, may not perform as reliably as
colectomy specimens if they contain only a small per-
centage of tumor cells. Several new methods of mutation
detection have been reported [3,8-13] and may be better
suited to samples with a low percentage of tumor cells.
Our results are in agreement with previous studies [8-
12], including a recent report by Oliner et al. [13] who
evaluated five commercial laboratories, one of which
(Genzyme) was also included in our study. They tested
forty FFPE samples from several tissue procurement pro-
viders, whereas our samples were obtained from colecto-
mies performed at our own clinic facilities, previously
tested, and used to guide clinical care. Because we were
able to select our samples based on mutation status, and
thus oversample for the KRAS mutations of interest, our
estimate of the agreement across laboratories corre-
sponds to an estimate from an effectively larger sample
size. It is reassuring that, while both studies evaluated
different commercial laboratories and used slightly dif-
ferent methodologies, both found good agreement across
testing facilities.
The commercial and academic-based laboratories
included in this study provide reliable test results for
common mutations in the KRAS gene from samples with
an adequate percentage of tumor cells. Discrepanciesobserved are likely due to either tumor heterogeneity, or
contamination of the tumor sample with normal tissue.
Both of these sources of variability are likely to be
encountered in the clinical setting, and may have import-
ant consequences for treatment decisions.
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